AU2022358998B2 - Methods and products for treating subjects with autism spectrum disorders - Google Patents

Methods and products for treating subjects with autism spectrum disorders

Info

Publication number
AU2022358998B2
AU2022358998B2 AU2022358998A AU2022358998A AU2022358998B2 AU 2022358998 B2 AU2022358998 B2 AU 2022358998B2 AU 2022358998 A AU2022358998 A AU 2022358998A AU 2022358998 A AU2022358998 A AU 2022358998A AU 2022358998 B2 AU2022358998 B2 AU 2022358998B2
Authority
AU
Australia
Prior art keywords
ticagrelor
acid
odt
agent
odf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022358998A
Other languages
English (en)
Other versions
AU2022358998A1 (en
Inventor
Moshe Laudon
Nava Zisapel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of AU2022358998A1 publication Critical patent/AU2022358998A1/en
Application granted granted Critical
Publication of AU2022358998B2 publication Critical patent/AU2022358998B2/en
Priority to AU2025242229A priority Critical patent/AU2025242229A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022358998A 2021-10-04 2022-10-03 Methods and products for treating subjects with autism spectrum disorders Active AU2022358998B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025242229A AU2025242229A1 (en) 2021-10-04 2025-10-03 Methods and products for treating subjects with autism spectrum disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163251935P 2021-10-04 2021-10-04
US63/251,935 2021-10-04
PCT/IB2022/059429 WO2023057879A1 (en) 2021-10-04 2022-10-03 Methods and products for treating subjects with autism spectrum disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025242229A Division AU2025242229A1 (en) 2021-10-04 2025-10-03 Methods and products for treating subjects with autism spectrum disorders

Publications (2)

Publication Number Publication Date
AU2022358998A1 AU2022358998A1 (en) 2024-04-11
AU2022358998B2 true AU2022358998B2 (en) 2025-09-11

Family

ID=83688729

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022358998A Active AU2022358998B2 (en) 2021-10-04 2022-10-03 Methods and products for treating subjects with autism spectrum disorders
AU2025242229A Pending AU2025242229A1 (en) 2021-10-04 2025-10-03 Methods and products for treating subjects with autism spectrum disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025242229A Pending AU2025242229A1 (en) 2021-10-04 2025-10-03 Methods and products for treating subjects with autism spectrum disorders

Country Status (16)

Country Link
US (1) US11878016B2 (cg-RX-API-DMAC10.html)
EP (1) EP4412616A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024536341A (cg-RX-API-DMAC10.html)
KR (1) KR20240089377A (cg-RX-API-DMAC10.html)
CN (1) CN118265521A (cg-RX-API-DMAC10.html)
AU (2) AU2022358998B2 (cg-RX-API-DMAC10.html)
CA (1) CA3232273A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000992A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024005762A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240184A (cg-RX-API-DMAC10.html)
EC (1) ECSP24033949A (cg-RX-API-DMAC10.html)
IL (1) IL311681B2 (cg-RX-API-DMAC10.html)
MX (1) MX2024004150A (cg-RX-API-DMAC10.html)
PE (1) PE20241338A1 (cg-RX-API-DMAC10.html)
TW (1) TW202322821A (cg-RX-API-DMAC10.html)
WO (1) WO2023057879A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051399A1 (en) * 2023-09-10 2025-03-13 Dafechem Ltd Liquid ticagrelor formulation
WO2025247961A1 (en) * 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105943515A (zh) * 2016-06-24 2016-09-21 山东鲁抗医药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法
US20190117577A1 (en) * 2016-04-21 2019-04-25 Astrazeneca Ab Orally disintegrating tablets
KR102007731B1 (ko) * 2018-02-12 2019-08-06 충남대학교산학협력단 티카그렐러를 포함하는 자가 미세유화 약물전달시스템 조성물 및 이의 제조방법
US10614684B2 (en) * 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233966B2 (en) * 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN104971042B (zh) 2014-04-04 2018-01-05 中国医学科学院医药生物技术研究所 替格瑞洛口服自微乳组合物
CN104434931A (zh) * 2014-11-06 2015-03-25 南京华威医药科技开发有限公司 含替格瑞洛和阿司匹林的复方口服固体剂及其制备方法
CN105669674A (zh) * 2014-11-21 2016-06-15 重庆圣华曦药业股份有限公司 一种替卡格雷新晶型及其在药物制剂中的应用
CN108078944A (zh) * 2016-11-22 2018-05-29 重庆植恩药业有限公司 含有替格瑞洛的固体组合物及其制备方法
TR201617983A2 (tr) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
EP3700525A4 (en) * 2017-10-27 2021-08-25 Beyond Barriers Therapeutics, Inc. IMPROVED PROVISION OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH OXIDATIVE STRESS
CN110876750A (zh) * 2018-09-06 2020-03-13 江苏恒瑞医药股份有限公司 一种含有替格瑞洛或其可药用盐的缓释组合物
CA3179635A1 (en) * 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190117577A1 (en) * 2016-04-21 2019-04-25 Astrazeneca Ab Orally disintegrating tablets
CN105943515A (zh) * 2016-06-24 2016-09-21 山东鲁抗医药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法
US10614684B2 (en) * 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP
KR102007731B1 (ko) * 2018-02-12 2019-08-06 충남대학교산학협력단 티카그렐러를 포함하는 자가 미세유화 약물전달시스템 조성물 및 이의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NA YOUNG-GUK ET AL: "Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor", INTERNATIONAL JOURNAL OF NANOMEDICINE, 2019, vol.14, pgs. 1193 - 1212 *

Also Published As

Publication number Publication date
IL311681B1 (en) 2025-10-01
KR20240089377A (ko) 2024-06-20
IL311681B2 (en) 2026-02-01
CR20240184A (es) 2024-07-03
MX2024004150A (es) 2024-04-22
EP4412616A1 (en) 2024-08-14
TW202322821A (zh) 2023-06-16
CO2024005762A2 (es) 2024-05-30
US20230105540A1 (en) 2023-04-06
CA3232273A1 (en) 2023-04-13
CL2024000992A1 (es) 2024-09-13
US11878016B2 (en) 2024-01-23
JP2024536341A (ja) 2024-10-04
CN118265521A (zh) 2024-06-28
PE20241338A1 (es) 2024-07-03
AU2025242229A1 (en) 2025-10-23
AU2022358998A1 (en) 2024-04-11
IL311681A (en) 2024-05-01
WO2023057879A1 (en) 2023-04-13
ECSP24033949A (es) 2024-06-28

Similar Documents

Publication Publication Date Title
EP1809251B1 (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
JP5604304B2 (ja) 口腔内崩壊性固形製剤
JP5572616B2 (ja) 口腔内分散性多層錠剤
RU2554740C2 (ru) Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств
US8962022B2 (en) Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
KR101125268B1 (ko) 구강 분산성 다중층 정제
US20250228833A1 (en) Methods and compositions for treating agitation
US20100233278A1 (en) Rapidly disintegrating solid preparation
JP2009114113A (ja) 口腔内崩壊錠及びその製造方法
US20120328675A1 (en) Film preparation containing medicament with unpleasant taste
EP2417969A1 (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
JPWO2008081891A1 (ja) 口腔内崩壊性固形製剤
AU2025242229A1 (en) Methods and products for treating subjects with autism spectrum disorders
US20200390709A1 (en) Procedure for preparing enteric-coated pellets containing a proton pump inhibitor and multi-particle pharmaceutical compositions containing them
US20060153925A1 (en) Novel solid pharmaceutical composition comprising amisulpride
WO2023067620A1 (en) Orally disintegrating pharmaceutical compositions of rivaroxaban
US20130143912A1 (en) Sublingual zolpidem formulations
JP2025529123A (ja) 急性ストレス障害を処置するための方法及び組成物
HK1154515A (en) Taste-masked multiparticulate pharmaceutical composition comprising a drug-containing core particle and a solvent-coacervated membrane
HK1107272B (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
JP2010100550A (ja) 医薬組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)